BPC-157 | Peptide Reference Material
RESEARCH PEPTIDE

BPC-157 | Peptide Reference Material

Cytoprotective Pentadecapeptide — Research Peptide
$29.00
Synthetic pentadecapeptide supplied as a lyophilized laboratory reference material for preclinical signaling and cell-model research. Research use only. Not for human or veterinary use.
✓ Identity Verified
✓ Batch Documentation
✓ QR Lot Verification
✓ Research Use Only
✓ U.S. Fulfillment
✓ Batch Verification Available View verification →
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
137525-51-0
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

BPC-157 is the synthetic pentadecapeptide GEPPPGKPADDAGLV, supplied as a laboratory peptide reference material. Research use only.

Primary Research Category
Analytical Sciences
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Identity Verification Receptor Pharmacology Analytical Chemistry

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

Preclinical studies associate BPC-157 with promotion of fibroblast outgrowth, cell survival and migration in tendon models (Chang et al., 2011), upregulation of growth hormone receptor expression in tendon fibroblasts (Chang et al., 2014), and pro-angiogenic activity linked to VEGFR2 activation and downstream endothelial signaling (Hsieh et al., 2017).

Reported mechanisms in the preclinical literature additionally include modulation of nitric-oxide-system pathways and cytoprotective vascular recruitment responses to injury.

Primary Organ Systems
  • Connective Tissue
  • Musculoskeletal System
  • Gastrointestinal System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

Batch Verified
Independent Batch Verification

Independent laboratory verification for this batch:

  • Identity Confirmation
  • HPLC Purity Analysis
  • Net Peptide Content
  • Endotoxin Testing
  • Analytical Chromatogram
  • Independent Laboratory Verification
View Batch Verification →
Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Source-supported research categories for this laboratory reference material.

Evidence Level
Evidence Landscape

Published BPC-157 research spans laboratory, animal, and a small number of human reports. A 2025 systematic review included 36 studies through June 2024: 35 preclinical and 1 clinical. This distribution should remain explicit when interpreting the literature.

Browse References →
Preclinical
Mechanistic Model Research

In one primary study, BPC-157 was evaluated in cultured human vascular endothelial cells, chick chorioallantoic membrane, and rat hind-limb ischemia systems. The authors reported VEGFR2/Akt/eNOS-associated laboratory endpoints and model-specific vascular or perfusion findings. These nonclinical results do not demonstrate a clinical effect in people.

Browse References →
Animal Evidence
Preclinical Toxicology Context

A multi-species nonclinical toxicology study reported findings under tested conditions, including mild local irritation and a reversible creatinine decrease at 2 mg/kg in dogs. Animal toxicology cannot establish human safety, long-term safety, product quality, or safety of any route or formulation.

Evidence Limitation
Human Evidence Limitations

Selected indexed human reports are small, uncontrolled, and context-specific. They cannot establish efficacy, generalizable safety, comparative benefit, or appropriate use. No randomized, adequately powered human efficacy trial was identified in the curated evidence package.

Research Gap
Open Research Questions

Key unanswered questions include reproducibility of preclinical findings, exposure-response relationships, validated endpoints, comparative controls, adverse-event capture, long-term follow-up, formulation comparability, and independently replicated human research.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Mechanistic Study•Journal of Molecular Medicine (Berlin)

Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95(3):323-333.

BPC-157 was evaluated in endothelial-cell, chick chorioallantoic membrane, and rat hind-limb ischemia systems. Authors reported VEGFR2-related signaling and vascular/perfusion-associated endpoints within those models. Mechanistic and nonclinical only; no human efficacy or safety conclusion follows.
Velora Research Insight
BPC-157-specific scientific context. Mechanistic and nonclinical only; no human efficacy or safety conclusion follows. This publication does not characterize the identity, purity, composition, or performance of a Velora lot.
PubMed →DOI →
Preclinical Study•Regulatory Toxicology and Pharmacology

Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665.

Single- and repeated-dose toxicology, local tolerance, genetic toxicity, and embryo-fetal toxicity were evaluated in mice, rats, rabbits, and dogs. The report described no serious toxicity under its study conditions, while noting mild local irritation and a reversible dog creatinine finding at 2 mg/kg. Animal findings do not establish human safety or safety of commercial research materials.
Velora Research Insight
BPC-157-specific scientific context. Animal findings do not establish human safety or safety of commercial research materials. This publication does not characterize the identity, purity, composition, or performance of a Velora lot.
PubMed →DOI →
Case Study•Alternative Therapies in Health and Medicine

Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13.

A single-clinic chart review contacted 16 people after intra-articular exposure (12 BPC-157 alone; 4 BPC-157 plus thymosin-beta-4). Outcomes were patient-reported and follow-up timing varied. No control group, small mixed-diagnosis cohort, co-intervention in part of the cohort, nonstandardized outcomes, and retrospective follow-up preclude efficacy or safety conclusions.
Velora Research Insight
BPC-157-specific scientific context. No control group, small mixed-diagnosis cohort, co-intervention in part of the cohort, nonstandardized outcomes, and retrospective follow-up preclude efficacy or safety conclusions. This publication does not characterize the identity, purity, composition, or performance of a Velora lot.
PubMed →DOI →
Case Study•Alternative Therapies in Health and Medicine

Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12-17.

Twelve women at one private clinic received a single procedure involving BPC-157 around areas of bladder inflammation; results used patient-reported Global Response Assessment with short follow-up. Small, single-site, uncontrolled report with subjective outcome assessment; it cannot establish efficacy, generalizability, comparative benefit, or long-term safety.
Velora Research Insight
BPC-157-specific scientific context. Small, single-site, uncontrolled report with subjective outcome assessment; it cannot establish efficacy, generalizability, comparative benefit, or long-term safety. This publication does not characterize the identity, purity, composition, or performance of a Velora lot.
PubMed →DOI →
Systematic Review•HSS Journal

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485-495.

A 2025 systematic review searched PubMed, Embase, and Cochrane through June 3, 2024, and included 36 studies—35 preclinical and 1 clinical—covering mechanism, musculoskeletal outcomes, metabolism, and safety. Review conclusion is constrained by predominantly preclinical, heterogeneous, low-level evidence and very limited human data.
Velora Research Insight
BPC-157-specific scientific context. Review conclusion is constrained by predominantly preclinical, heterogeneous, low-level evidence and very limited human data. This publication does not characterize the identity, purity, composition, or performance of a Velora lot.
PubMed →DOI →